AI Article Synopsis

  • The swine industry has improved over the years, focusing on increasing the number of piglets born, but this has led to more underweight and weaker piglets, resulting in lower survival rates.
  • Researchers developed a new vaginal drug delivery system using two types of cloprostenol tablets—a fast-releasing one and a slow-releasing one—to induce pig farrowing more effectively while avoiding non-therapeutic injectables.
  • In tests with various groups of sows, the drug release system showed promise in managing the timing of farrowing, although the treated groups tended to take longer to give birth compared to the control group.

Article Abstract

The swine industry has evolved significantly in the recent decades, but this has come at considerable expense to piglet survival. Breeding sows for greater prolificacy has been accompanied by a greater proportion of piglets being born underweight, of lower vigor, and higher susceptibility to early mortality. Inducing sows to farrow during working hours has the potential to increase piglet survivability, but non-therapeutic injectable products are often discouraged on farms. We aimed to design and develop a novel vaginal drug delivery system (NVDDS) that could reliably trigger luteolysis and induce parturition. To achieve this, two vaginal tablets containing the luteolytic agent cloprostenol were formulated to be inserted together: one would release constituents immediately on insertion (immediate release; IR) and the other would release cloprostenol in a controlled manner (controlled release; CR). The two formulations (IR and CR) were evaluated for drug release, swelling and bio-adhesion in conditions simulating the sow vaginal environment. The IR tablet released the drug completely for 5 min whereas the CR tablet took 5 h to release 50% of the drug. Furthermore, the release kinetics were evaluated by fitting the dissolution profiles into different mathematical models. Both IR and CR tablets were best fitted by the Makoid-Banakar model which assumes release by summation of different mechanisms. The performance of the optimized formulations was studied in vivo with 161 Large White x Landrace sows of varying parity (0-5). The sows were assigned to five groups. Group 1 (SI) received a single vulval injection of cloprostenol at 0700 h ( = 32), group 2 (SDI) received the same dose split in two parts, at 0700h and 1300h ( = 33). Group 3 (IRT) animals were administered an IR tablet at 0700h ( = 32), while group 4 (IRCRT) received both IR and CR tablets at 0700 h ( = 33). Group 5 was untreated and served as a control ( = 32). The interval to farrowing was longer ( < 0.001) for controls than for treated sows, but there were no differences among cloprostenol treatments for timing of farrowing. The finding confirms the efficacy of the NVDDS for induction of farrowing in sows.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874451PMC
http://dx.doi.org/10.3390/pharmaceutics14020340DOI Listing

Publication Analysis

Top Keywords

novel vaginal
8
vaginal drug
8
drug delivery
8
delivery system
8
release
8
drug release
8
0700 group
8
sows
6
drug
5
group
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!